Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long‐term follow‐up study. (15th November 2012)

• Record Type: Journal Article
• Authors: Sahebi, Firoozeh; Shen, Yan; Thomas, Sandra H.; Rincon, Amalia; Murata‐Collins, Joyce; Palmer, Joycelynne; Krishnan, Amrita Y.; Karanes, Chatchada; Htut, Myo; Somlo, George; Forman, Stephen J.
• Is Part Of: British journal of haematology. Volume 160:Number 2(2013:Jan.)
• Page Start: 199
• Page End: 206
• Publication Date: 2012-11-15
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.12123
• Languages: English
• ISSNs: 0007-1048

Abstract

<abstract abstract-type="main" id="bjh12123-abs-0001"> <title>Summary</title> <p>We analysed the long‐term outcomes of 60 multiple myeloma patients who underwent reduced intensity allogeneic stem cell transplantation between August 2000 and March 2008. Regimens included fludarabine and melphalan conditioning (flu‐mel regimen) for allogeneic haematopoietic cell transplant (HCT) or a planned tandem regimen consisting of high‐dose melphalan conditioning for autograft followed by low‐dose total body irradiation conditioning for allogeneic HCT (auto‐allo regimen). Donors included human‐leucocyte‐antigen‐matched siblings (<italic>n</italic> = 55) or matched unrelated donors (<italic>n</italic> = 5). With a median follow‐up of 9·8 years, 7‐year overall survival (OS) and progression‐free survival (PFS) were 60% and 31%, respectively. By multivariate Cox regression analysis, disease status of complete response (CR) or partial response (PR) at transplant and the presence of chronic graft‐<italic>versus</italic>‐host disease were significantly associated with improved OS. Only disease status was significantly associated with improved PFS. We noted a surprising number of very late relapses, with six patients (10%) relapsing between 6 and 12 years post‐transplant. Among the six late relapse patients, all were transplanted within 14 months of diagnosis, five had normal karyotypes, and five were in CR/PR. Our data provide additional evidence that, while survival may be extended by reduced intensity allogeneic transplant, ultimately, it may not offer a cure.</p> </abstract>